

April 2, 2024

VIA EDGAR

U.S. Securities and Exchange Commission
Division of Corporation Finance
Mail Stop 4561
100 F Street, N.E.
Washington, D.C. 20549-3720

Attention: Daniel Crawford
Laura Crotty
Ibolya Ignat
Kevin Juhar

Re: Contineum Therapeutics, Inc.
Amendment No. 1 to Registration Statement on Form S-1
Filed April 1, 2024
File No. 333-278003
CIK No: 0001855175

Request for Acceleration of Effective Date

Requested Date: Thursday, April 4, 2024
Requested Time: 4:00 P.M. Eastern Time

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Contineum Therapeutics, Inc. (the “**Company**”) hereby requests that the above-referenced Registration Statement on Form S-1 (File No. 333-278003) (the “**Registration Statement**”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, by calling Ryan Gunderson at (858) 436-8046.

[Signature page follows]

Sincerely,

Contineum Therapeutics, Inc.

By: /s/ Peter Slover

Peter Slover
Chief Financial Officer
Contineum Therapeutics, Inc.

cc: Carmine Stengone, Chief Executive Officer and President, Contineum Therapeutics, Inc.
Jeffrey Thacker, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP
Ryan J. Gunderson, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP
Leanne A. Gould, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP
Frank F. Rahmani, Sidley Austin LLP
Samir A. Gandhi, Sidley Austin LLP
J. Carlton Fleming, Sidley Austin LLP
Kostian Ciko, Sidley Austin LLP